# Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Source: https://onco.cc/trials/nct00884273/  
OnCo record `nct00884273` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.

## Summary

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients is a phase 3 interventional study registered as NCT00884273 by Ferring Pharmaceuticals, with 182 participants recorded, started 2009-08 and reaching its primary completion in 2011-03. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.

Linked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00884273
- Phase: 3
- Setting: A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration
- Sponsor: Ferring Pharmaceuticals
- Enrolled: 182

## Sources

- ClinicalTrials.gov NCT00884273: https://clinicaltrials.gov/study/NCT00884273

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Bicalutamide](https://onco.cc/drugs/bicalutamide/), [Degarelix](https://onco.cc/drugs/degarelix/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/)
- companies: [Ferring Pharmaceuticals](https://onco.cc/companies/ferring/)

---
JSON: https://onco.cc/api/v1/entities/nct00884273.json